ArticleComputational and structural biotechnology journal2024
Uncovering the potential of APOD as a biomarker in gastric cancer: A retrospective and multi-center study.
Article in Computational and structural biotechnology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 22 citations in OpenAlex.
- Systemic Molecular Network Alterations Associated with FoxA2 in Gastric Cancer.International journal of molecular sciences · 2026Article
- Multi-omics investigation of benzo[a]pyrene in gastric cancer: comprehensive network toxicology, machine learning and molecular docking approaches.Molecular diversity · 2026Article
- Establishment and validation of a prognostic model based on liquid-liquid phase separation-related genes in gastric cancer.Translational cancer research · 2026Article
- A Novel CAF-Related Signature for Precise Prediction of Clinical Outcomes and Immunotherapy Response for Breast Cancer Patients: Based on Multiomics Analyses and Experimental Validation.Mediators of inflammation · 2026Article
- Integrative Analysis of Steroid Metabolism-Based Molecular Subtypes Reveals Prognostic Subtypes and Therapeutic Implications in Gastric Cancer.Cancer informatics · 2026Article
- An integrative analysis of UFMylation-related genes reveals a prognostic signature and identifies GDF7 as a novel therapeutic target in gastric cancer.Frontiers in oncology · 2026Article
- Clinical Significance of SDC2 in Gastric Cancer: Insights From a Multi-Center Cohort Study.Cancer informatics · 2026Article
- Identification of a lactylation-related gene signature in microsatellite stable gastric cancer based on bulk and single-cell RNA-seq.Frontiers in immunology · 2026Article
- Identification of predictive pretreatment biomarkers for neoadjuvant chemotherapy response in Latino invasive breast cancer patients.Molecular medicine (Cambridge, Mass.) · 2025Article
- Identification of oxidative stress-related genes in papillary thyroid carcinoma and their common targets with resveratrol based on bioinformatics, network pharmacology, and molecular docking.Discover oncology · 2025Article
- Exploring the evolving role of apolipoproteins in oncology: global trends and emerging frontiers.Journal of cancer research and clinical oncology · 2025Article
- Shared molecular mechanisms between type 2 diabetes and thyroid cancer: integrated bioinformatics insights for prognostic biomarker discovery.Endocrine connections · 2025Article
- ApoD mediates age-associated increase in vulnerability to influenza virus infection.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- Correlation between dyslipidaemia and gastric cancer: pathogenesis to prevention and treatment strategies.Lipids in health and disease · 2025Review
- Identification of a Biomarker Panel in Extracellular Vesicles Derived From Non-Small Cell Lung Cancer (NSCLC) Through Proteomic Analysis and Machine Learning.Journal of extracellular vesicles · 2025Article
- Integrating multiomics analysis and machine learning to refine the molecular subtyping and prognostic analysis of stomach adenocarcinoma.Scientific reports · 2025Article
- The impact of aberrant lipid metabolism on the immune microenvironment of gastric cancer: a mini review.Frontiers in immunology · 2025Review
- Development and validation of an ARID1A-related immune genes risk model in evaluating prognosis and immune therapeutic efficacy for gastric cancer patients: a translational study.Frontiers in immunology · 2025Article
- The mRNA MOXD1: Link to oxidative stress and prognostic significance in gastric cancer.Open medicine (Warsaw, Poland) · 2025Article
- Role of disulfide death in cancer (Review).Oncology letters · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gastric cancer (GC) poses a significant health challenge worldwide, necessitating the identification of predictive biomarkers to improve prognosis. Dysregulated lipid metabolism is a well-recognized hallmark of tumorigenesis, prompting investigation into apolipoproteins (APOs). In this study, we focused on apolipoprotein D (APOD) following comprehensive analyses of APOs in pan-cancer. Utilizing data from the TCGA-STAD and GSE62254 cohorts, we elucidated associations between APOD expression and multiple facets of GC, including prognosis, tumor microenvironment (TME), cancer biomarkers, mutations, and immunotherapy response, and identified potential anti-GC drugs. Single-cell analyses and immunohistochemical staining confirmed APOD expression in fibroblasts within the GC microenvironment. Additionally, we independently validated the prognostic significance of APOD in the ZN-GC cohort. Our comprehensive analyses revealed that high APOD expression in GC patients was notably associated with unfavorable clinical outcomes, reduced microsatellite instability and tumor mutation burden, alterations in the TME, and diminished response to immunotherapy. These findings provide valuable insights into the potential prognostic and therapeutic implications of APOD in GC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.